Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 5Terminated 3Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 26Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid 2Renal Insufficiency, Chronic 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Older Patients 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 6fludarabine 5Rituximab 4obinutuzumab 3tafasitamab 2relmacabtagene autoleucel 2pirtobrutinib 2zanubrutinib 1venetoclax 1tisagenlecleucel 1resiniferatoxin 1pomalidomide 1polatuzumab vedotin 1glofitamab 1Vincristine 1Tretinoin 1Surveys and Questionnaires 1Specimen Handling 1Radiotherapy 1Prednisolone 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1Doxorubicin 1Dexamethasone 1Blood Specimen Collection 1Bendamustine Hydrochloride 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, B-Cell × venetoclax × Clear all
NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Nurix Therapeutics, Inc.

Phase 1/2 Not yet recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡